Collins James J. has filed 5 insider transactions across 2 companies since June 2023.
Most recent transaction: a grant/award of 21950 shares of Senti Biosciences, Inc. ($SNTI) on June 25, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 25, 2025 | Senti Biosciences, Inc. | $SNTI | Collins James J. | Not found | A | Stock Option (Right to Buy) | 21950 | $0.00 | 21,950.0000 | 26,004,366 | 9999.99% | 0.08% |
| March 7, 2025 | Senti Biosciences, Inc. | $SNTI | Collins James J. | Director | A | Stock Option (Right to Buy) | 43900 | $0.00 | 43,900.0000 | 4,829,035 | 9999.99% | 0.91% |
| July 10, 2024 | Senti Biosciences, Inc. | $SNTI | Collins James J. | Director | A | Stock Option (Right to Buy) | 62500 | $0.00 | 62,500.0000 | 4,572,432 | 9999.99% | 1.37% |
| June 17, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Collins James J. | Not found | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 61,310 | 9999.99% | 48.93% |
| June 16, 2023 | Senti Biosciences, Inc. | $SNTI | Collins James J. | Director | A | Stock Option (Right to Buy) | 62500 | $0.00 | 62,500.0000 | 4,406,137 | 9999.99% | 1.42% |